Drug Profile
Research programme: pain therapies - ACADIA/AbbVie
Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator ACADIA Pharmaceuticals
- Class Small molecules
- Mechanism of Action Alpha adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 08 Oct 2015 Research programme: pain therapies - ACADIA/Allergan is available for licensing as of 26 Feb 2015. http://www.acadia-pharm.com/